Archer Aviation (NYSE: ACHR) is developing Midnight — an electric vertical takeoff and landing (eVTOL) aircraft designed for urban air mobility. The concept is compelling: quiet, zero-emission air taxis that can bypass ground traffic by flying point-to-point between vertipads in urban areas. The capital requirements are daunting: aircraft development, FAA certification, manufacturing scale-up, and vertipad infrastructure together represent billions of dollars in investment before a single commercial flight.
Archer Aviation is pre-revenue, pre-certification, and pre-commercial-operation — a pure development-stage company. This profile earns it a HIGH DilutionScore™ on DilutionWatch, as pre-revenue aerospace companies have essentially no alternative to equity markets for capital.
Archer Aviation is a development-stage company with no commercial revenue. Capital requirements are massive and ongoing. View ACHR's full DilutionScore™ →
Archer Aviation's public market journey has been characterized by SPAC merger and subsequent PIPE (Private Investment in Public Equity) transactions:
PIPE deals are worth understanding for public market investors: they allow private investors to buy shares at negotiated prices (often below market), providing capital to the company but immediately diluting existing public shareholders. The discount at which PIPE shares are issued is a direct transfer of value from public holders to PIPE participants.
PIPE transactions are often structured at 5-15% discounts to market price. Each PIPE deal transfers value from existing public shareholders to the PIPE investors, in addition to expanding the share count.
Archer's partnership with United Airlines is among its most prominently marketed strategic relationships — and understanding its nature is important for evaluating the company's capital situation:
The United partnership is genuinely valuable for Archer's commercial positioning, but investors should be precise: partnership announcements are not funding events. Archer's capital needs must still be met through equity and debt markets until commercial operations generate revenue.
FAA type certification for an eVTOL aircraft is an extraordinarily lengthy and expensive process — and the single largest variable in Archer's capital timeline:
Any slippage in the FAA certification timeline directly increases the total capital required to reach commercialization — and therefore increases the probability and magnitude of future equity raises. Monitor Archer's certification milestone disclosures closely.
Shelf Capacity: Active S-3 shelf; ATM + PIPE capability. Score: 21/25
Cash Runway: Pre-revenue; burning cash on certification and development. Score: 19/25
Float Risk: Share count grown substantially from SPAC + PIPE + ATM + SBC. Score: 15/20
Warrant Overhang: SPAC warrants + additional warrants outstanding. Score: 10/15
Convertible Exposure: Convertible instruments in capital structure. Score: 9/15
Total DilutionScore™: ~74/100 — HIGH RISK
Archer Aviation earns its HIGH DilutionScore™ through fundamental necessity: it is a pre-revenue, pre-certification aerospace company developing a novel aircraft in one of the most expensive regulatory environments on earth. Capital requirements over the next 3–5 years before commercial operations could total hundreds of millions to over a billion dollars — and virtually all of that will come from equity markets.
Investors in ACHR are making a long-duration bet on the eVTOL category, Midnight's certification success, and Archer's operational execution. The dilution is a known and expected cost of that bet. Model aggressive share count growth (15–25%+ annually) into any valuation framework for ACHR.
DilutionWatch provides maximum value for ACHR holders: early detection of PIPE registrations, S-3 filings, and ATM prospectus supplements gives investors visibility into the capital raise cadence before official announcements — critical intelligence for active ACHR position management.
See ACHR's live DilutionScore™ alongside every other stock in your portfolio. Get alerted the moment dilution risk changes.
Add Tickers Free →